Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Ipsen's Ojemda (tovorafenib) wins EU approval for relapsed or refractory pediatric low-grade glioma in Ph2
Small molecule, cancer, BRAF inhibitor, pediatric low-grade glioma, brain tumor - Read more

Sanofi's Tzield (teplizumab-mzwv) receives FDA label expansion for stage 3 type 1 diabetes delay in children as young as one
Antibody, autoimmune, monoclonal antibody, type 1 diabetes, pediatric population, CD3 target - Read more

Moderna's mCOMBRIAX (mRNA-1010/mNEXSPIKE) wins European Commission approval for influenza and COVID-19 combination immunization in adults 50 and older
Vaccine, infectious disease, mRNA vaccine, COVID-19, influenza, combination vaccine - Read more

Merck & Co., Google Cloud partner on enterprise-wide agentic AI transformation, investment valued up to $1B
Enterprise partnership, AI/ML, R&D, manufacturing, commercialization - Read more

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

Revolution Medicines' (daraxonrasib) shows Ph2 promise in first-line RAS-mutated pancreatic cancer as Ph3 trial begins enrolling
Small molecule, cancer, RAS inhibitor, pancreatic cancer, combination therapy - Read more

Ionis Pharmaceuticals' (zilganersen) Ph1-3 data show motor stabilization in Alexander disease ahead of FDA priority review
Antisense oligonucleotide, neurological, rare disease, Alexander disease, motor function - Read more

BridgeBio Oncology Therapeutics presents preclinical data for (BBO-11818) pan-KRAS inhibitor in KRAS-mutant solid tumors ahead of Ph1
Small molecule, cancer, KRAS inhibitor, pancreatic cancer, non-small cell lung cancer, colorectal cancer - Read more

OREGA Biotech's IPH5201 (IPH5201) Ph2 interim results show promising pathological complete response in resectable early-stage non-small cell lung cancer
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, CD39 target, combination therapy - Read more

Roche's fenebrutinib (fenebrutinib) Ph3 data shows record-low relapse rates in relapsing multiple sclerosis amid safety scrutiny
Small molecule, neurological, BTK inhibitor, multiple sclerosis, relapsing multiple sclerosis - Read more

AcuityMD raises $80M to bolster AI platform for medtech commercial operations
AI/ML platform, software platform, medtech, commercial analytics - Read more

Altimmune prices $225M public offering to fund Phase 3 MASH trial
MASH, liver disease, small molecule, clinical-stage - Read more

10x Science raises $4.8M seed round to build AI for molecular-level protein characterization
AI/ML platform, protein characterization, drug discovery, platform technology - Read more

Maze Therapeutics prices $150M equity offering to advance R&D pipeline
Rare disease, small molecule, platform-enabled, preclinical - Read more

AbbVie invests $1.4B to build 185-acre Durham, NC production hub, creating 730-plus jobs
Small molecule, immunology, major transaction, operational - Read more

Amneal acquires Kashiv BioSciences for $1.1B to expand biosimilars pipeline amid market growth
Biosimilar, oncology, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Eli Lilly exits Rigel Pharmaceuticals' RIPK1 alliance, forfeiting $835M milestones on two inhibitors
Licensing deal, small molecule, autoimmune, neurological, milestone payments - Read more

CMS postpones BALANCE GLP-1 pilot indefinitely, hitting Eli Lilly and Novo Nordisk stocks
GLP-1, obesity, regulatory, revenue impact - Read more

FDA issues warning letter to New Life Pharma after inspectors denied access to GLP-1 manufacturing facility
Small molecule, metabolic disease, regulatory, operational, manufacturing compliance - Read more

FDA extends review of Sanofi's Sarclisa (isatuximab-irfc) subcutaneous biologics license application for multiple myeloma
Antibody, cancer, monoclonal antibody, multiple myeloma, CD38 target, subcutaneous formulation - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here